CL2013001558A1 - El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. - Google Patents
El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.Info
- Publication number
- CL2013001558A1 CL2013001558A1 CL2013001558A CL2013001558A CL2013001558A1 CL 2013001558 A1 CL2013001558 A1 CL 2013001558A1 CL 2013001558 A CL2013001558 A CL 2013001558A CL 2013001558 A CL2013001558 A CL 2013001558A CL 2013001558 A1 CL2013001558 A1 CL 2013001558A1
- Authority
- CL
- Chile
- Prior art keywords
- beats
- minute
- approximately
- limit
- prevent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13967208P | 2008-12-22 | 2008-12-22 | |
US21853009P | 2009-06-19 | 2009-06-19 | |
US24671509P | 2009-09-29 | 2009-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013001558A1 true CL2013001558A1 (es) | 2013-10-25 |
Family
ID=41667217
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011001529A CL2011001529A1 (es) | 2008-12-22 | 2011-06-21 | Uso de un modulador o agonista de los receptores s1p derivado de 2-amino-propan-1,3-diol o 2-amino-propanol para tratar una enfermedad cronica larga en un sujeto, de manera de conseguir una disminucion diaria en la frecuencia cardiaca de 2 latidos/minutos o menos; y kit que lo comprende. |
CL2013001558A CL2013001558A1 (es) | 2008-12-22 | 2013-05-31 | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011001529A CL2011001529A1 (es) | 2008-12-22 | 2011-06-21 | Uso de un modulador o agonista de los receptores s1p derivado de 2-amino-propan-1,3-diol o 2-amino-propanol para tratar una enfermedad cronica larga en un sujeto, de manera de conseguir una disminucion diaria en la frecuencia cardiaca de 2 latidos/minutos o menos; y kit que lo comprende. |
Country Status (40)
Country | Link |
---|---|
US (11) | US20100160259A1 (es) |
EP (7) | EP3677260A1 (es) |
JP (6) | JP2012513401A (es) |
KR (1) | KR101347919B1 (es) |
CN (1) | CN102264359A (es) |
AR (1) | AR074826A1 (es) |
AU (1) | AU2009330176C9 (es) |
BR (1) | BRPI0923500A2 (es) |
CA (1) | CA2747802C (es) |
CL (2) | CL2011001529A1 (es) |
CO (1) | CO6390117A2 (es) |
CR (1) | CR20110274A (es) |
CU (1) | CU20110136A7 (es) |
CY (4) | CY1116990T1 (es) |
DK (3) | DK3453387T3 (es) |
EA (1) | EA201100978A1 (es) |
EC (1) | ECSP11011222A (es) |
ES (3) | ES2810823T3 (es) |
FR (1) | FR20C1060I1 (es) |
HN (1) | HN2011001759A (es) |
HR (3) | HRP20151190T1 (es) |
HU (4) | HUE026869T2 (es) |
IL (3) | IL213170A0 (es) |
LT (3) | LT3409274T (es) |
MA (1) | MA32981B1 (es) |
ME (2) | ME03594B (es) |
MX (2) | MX2011006623A (es) |
NO (1) | NO2020038I1 (es) |
NZ (1) | NZ593065A (es) |
PE (1) | PE20120337A1 (es) |
PL (3) | PL3409274T3 (es) |
PT (3) | PT3409274T (es) |
RS (2) | RS60666B1 (es) |
SG (1) | SG171404A1 (es) |
SI (3) | SI2379067T1 (es) |
TN (1) | TN2011000272A1 (es) |
TW (1) | TW201028143A (es) |
UY (1) | UY32352A (es) |
WO (1) | WO2010075239A1 (es) |
ZA (2) | ZA201103863B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101718639B1 (ko) | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 s1p₁ 수용체 작동약에 대한 투약 섭생 |
CA2747802C (en) | 2008-12-22 | 2021-02-09 | Novartis Ag | Dosage regimen for a s1p receptor agonist |
EP3047848A1 (en) | 2009-09-29 | 2016-07-27 | Novartis AG | Dosage regimen of an s1p receptor modulator |
US20110124605A1 (en) * | 2009-11-20 | 2011-05-26 | Shreeram Aradhye | Use of an S1P Receptor Agonist |
EP3378854B1 (en) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
EP2566473B1 (en) * | 2010-05-06 | 2016-01-06 | Novartis AG | Dosage regimen of diaryl sulfide derivatives |
EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
FR2968556B1 (fr) | 2010-12-13 | 2013-12-27 | Centre Nat Rech Scient | Inhibiteurs des infections a vih et leurs utilisations |
JP6133790B2 (ja) | 2011-02-18 | 2017-05-24 | ザ スクリプス リサーチ インスティテュート | ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 |
AR085749A1 (es) | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
US9592268B2 (en) | 2011-05-23 | 2017-03-14 | Cornell University | Endothelium protective materials and methods of use |
TW201320994A (zh) | 2011-10-11 | 2013-06-01 | Novartis Ag | 投藥療程 |
CN104540800B (zh) | 2012-08-17 | 2017-05-10 | 埃科特莱茵药品有限公司 | 制备(2z,5z)‑5‑(3‑氯‑4‑((r)‑2,3‑二羟基丙氧基)苯亚甲基)‑2‑(丙亚氨基)‑3‑(邻甲苯基)噻唑烷‑4‑酮的方法及在该方法中所用的中间产物 |
WO2014138502A1 (en) * | 2013-03-06 | 2014-09-12 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure |
KR101820330B1 (ko) | 2013-10-11 | 2018-01-19 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 국소 스핑고신-1-포스페이트 수용체 효현제 제형 및 이의 사용 방법 |
WO2015053879A1 (en) | 2013-10-11 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
CN116650467A (zh) * | 2014-04-10 | 2023-08-29 | 诺华股份有限公司 | S1p调节剂的立即释放剂量方案 |
EA036075B1 (ru) | 2014-12-11 | 2020-09-23 | Актелион Фармасьютиклз Лтд | Схема дозирования для селективного агониста рецептора s1p1 |
US11007175B2 (en) * | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
NZ738862A (en) | 2015-06-22 | 2023-12-22 | Arena Pharm Inc | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders |
EP3582814A1 (en) | 2017-02-16 | 2019-12-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
EP4051250A1 (en) | 2019-10-31 | 2022-09-07 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
WO2021158848A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor agonist |
WO2021158838A1 (en) | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor modulator |
CN113332435B (zh) * | 2021-06-18 | 2022-10-18 | 广州中医药大学(广州中医药研究院) | 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0627406T3 (da) | 1992-10-21 | 1999-07-12 | Taito Co | 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler |
CA2421893A1 (en) | 2000-08-31 | 2002-03-07 | Merck And Co., Inc. | Phosphate derivatives as immunoregulatory agents |
BR0311173A (pt) | 2002-05-16 | 2005-03-15 | Novartis Ag | Uso de agentes de ligação do receptor de edg em câncer |
CA2539033C (en) * | 2003-09-12 | 2013-03-05 | Neuronova Ab | Treatment of disease or injury of the nervous system with fty720 |
US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
EP2384749A1 (en) * | 2004-11-29 | 2011-11-09 | Novartis AG | Dosage regimen of an S1P receptor agonist |
EP1688141A1 (en) * | 2005-01-31 | 2006-08-09 | elbion AG | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
EP1850689A4 (en) * | 2005-02-10 | 2013-05-22 | G I View Ltd | TECHNIQUES FOR DISPLACING A GASTROINTESTINAL TOOL EQUIPPED WITH A GUIDING ELEMENT |
EP3733162A1 (en) | 2007-10-12 | 2020-11-04 | Novartis AG | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
KR101718639B1 (ko) * | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 s1p₁ 수용체 작동약에 대한 투약 섭생 |
US20110152380A1 (en) * | 2008-06-20 | 2011-06-23 | Kovarik John M | Paediatric Compositions For Treating Multiple Sclerosis |
SG171888A1 (en) * | 2008-12-22 | 2011-07-28 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
CA2747802C (en) | 2008-12-22 | 2021-02-09 | Novartis Ag | Dosage regimen for a s1p receptor agonist |
-
2009
- 2009-12-21 CA CA2747802A patent/CA2747802C/en active Active
- 2009-12-21 SI SI200931311T patent/SI2379067T1/sl unknown
- 2009-12-21 CN CN2009801518640A patent/CN102264359A/zh active Pending
- 2009-12-21 PL PL18179301T patent/PL3409274T3/pl unknown
- 2009-12-21 AR ARP090105010A patent/AR074826A1/es not_active Application Discontinuation
- 2009-12-21 AU AU2009330176A patent/AU2009330176C9/en not_active Withdrawn - After Issue
- 2009-12-21 SG SG2011037629A patent/SG171404A1/en unknown
- 2009-12-21 HU HUE09797234A patent/HUE026869T2/en unknown
- 2009-12-21 RS RS20200900A patent/RS60666B1/sr unknown
- 2009-12-21 HU HUE18179301A patent/HUE048717T4/hu unknown
- 2009-12-21 ME MEP-2019-339A patent/ME03594B/me unknown
- 2009-12-21 WO PCT/US2009/068888 patent/WO2010075239A1/en active Application Filing
- 2009-12-21 EP EP20160225.7A patent/EP3677260A1/en active Pending
- 2009-12-21 JP JP2011542521A patent/JP2012513401A/ja not_active Withdrawn
- 2009-12-21 PT PT181793019T patent/PT3409274T/pt unknown
- 2009-12-21 PL PL09797234T patent/PL2379067T3/pl unknown
- 2009-12-21 US US12/642,892 patent/US20100160259A1/en not_active Abandoned
- 2009-12-21 LT LTEP18179301.9T patent/LT3409274T/lt unknown
- 2009-12-21 DK DK18201062.9T patent/DK3453387T3/da active
- 2009-12-21 RS RS20191546A patent/RS59857B1/sr unknown
- 2009-12-21 PE PE2011001265A patent/PE20120337A1/es not_active Application Discontinuation
- 2009-12-21 ES ES18201062T patent/ES2810823T3/es active Active
- 2009-12-21 EP EP15158251.7A patent/EP2907511A1/en not_active Withdrawn
- 2009-12-21 NZ NZ593065A patent/NZ593065A/xx not_active IP Right Cessation
- 2009-12-21 EA EA201100978A patent/EA201100978A1/ru unknown
- 2009-12-21 DK DK18179301.9T patent/DK3409274T3/da active
- 2009-12-21 MX MX2011006623A patent/MX2011006623A/es unknown
- 2009-12-21 TW TW098143960A patent/TW201028143A/zh unknown
- 2009-12-21 PL PL18201062T patent/PL3453387T3/pl unknown
- 2009-12-21 KR KR1020117017073A patent/KR101347919B1/ko active IP Right Grant
- 2009-12-21 EP EP18179301.9A patent/EP3409274B1/en active Active
- 2009-12-21 EP EP09797234.3A patent/EP2379067B1/en not_active Revoked
- 2009-12-21 ES ES09797234.3T patent/ES2552823T3/es active Active
- 2009-12-21 EP EP18201062.9A patent/EP3453387B1/en active Active
- 2009-12-21 PT PT97972343T patent/PT2379067E/pt unknown
- 2009-12-21 SI SI200932080T patent/SI3453387T1/sl unknown
- 2009-12-21 ME MEP-2020-156A patent/ME03802B/me unknown
- 2009-12-21 PT PT182010629T patent/PT3453387T/pt unknown
- 2009-12-21 US US13/141,552 patent/US20110257133A1/en not_active Abandoned
- 2009-12-21 DK DK09797234.3T patent/DK2379067T3/en active
- 2009-12-21 UY UY0001032352A patent/UY32352A/es not_active Application Discontinuation
- 2009-12-21 LT LTEP18201062.9T patent/LT3453387T/lt unknown
- 2009-12-21 BR BRPI0923500-0A patent/BRPI0923500A2/pt not_active Application Discontinuation
- 2009-12-21 EP EP16182876.9A patent/EP3120844A1/en not_active Withdrawn
- 2009-12-21 EP EP22187007.4A patent/EP4098256A1/en active Pending
- 2009-12-21 ES ES18179301T patent/ES2760607T3/es active Active
- 2009-12-21 SI SI200932015T patent/SI3409274T1/sl unknown
- 2009-12-21 MA MA34034A patent/MA32981B1/fr unknown
- 2009-12-21 HU HUE18201062A patent/HUE052048T2/hu unknown
-
2011
- 2011-05-25 ZA ZA2011/03863A patent/ZA201103863B/en unknown
- 2011-05-25 CR CR20110274A patent/CR20110274A/es not_active Application Discontinuation
- 2011-05-26 TN TN2011000272A patent/TN2011000272A1/fr unknown
- 2011-05-26 IL IL213170A patent/IL213170A0/en unknown
- 2011-06-17 MX MX2021010759A patent/MX2021010759A/es unknown
- 2011-06-21 CL CL2011001529A patent/CL2011001529A1/es unknown
- 2011-06-22 CU CU20110136A patent/CU20110136A7/es unknown
- 2011-06-22 HN HN2011001759A patent/HN2011001759A/es unknown
- 2011-06-22 EC EC2011011222A patent/ECSP11011222A/es unknown
- 2011-06-23 CO CO11079290A patent/CO6390117A2/es not_active Application Discontinuation
-
2012
- 2012-08-06 ZA ZA2012/05942A patent/ZA201205942B/en unknown
-
2013
- 2013-05-31 CL CL2013001558A patent/CL2013001558A1/es unknown
- 2013-09-06 US US14/020,058 patent/US20140066657A1/en not_active Abandoned
-
2014
- 2014-01-31 US US14/169,660 patent/US20140148415A1/en not_active Abandoned
- 2014-04-10 JP JP2014080892A patent/JP2014144970A/ja not_active Withdrawn
-
2015
- 2015-10-14 JP JP2015202669A patent/JP2016135752A/ja not_active Withdrawn
- 2015-11-06 HR HRP20151190TT patent/HRP20151190T1/hr unknown
- 2015-11-30 CY CY20151101084T patent/CY1116990T1/el unknown
- 2015-12-02 US US14/956,855 patent/US20160081949A1/en not_active Abandoned
-
2016
- 2016-05-23 US US15/161,778 patent/US20160263061A1/en not_active Abandoned
-
2017
- 2017-03-06 JP JP2017041331A patent/JP2017141238A/ja not_active Withdrawn
- 2017-03-21 US US15/465,091 patent/US20170189353A1/en not_active Abandoned
-
2018
- 2018-06-11 US US16/005,137 patent/US20180289638A1/en not_active Abandoned
- 2018-11-26 US US16/199,905 patent/US20190091180A1/en not_active Abandoned
-
2019
- 2019-05-22 JP JP2019095899A patent/JP7329965B2/ja active Active
- 2019-12-02 HR HRP20192175TT patent/HRP20192175T1/hr unknown
- 2019-12-03 CY CY20191101264T patent/CY1122812T1/el unknown
-
2020
- 2020-05-05 US US16/867,293 patent/US20200330407A1/en not_active Abandoned
- 2020-05-18 IL IL274756A patent/IL274756A/en unknown
- 2020-07-27 HR HRP20201167TT patent/HRP20201167T1/hr unknown
- 2020-08-03 CY CY20201100712T patent/CY1123255T1/el unknown
- 2020-11-17 LT LTPA2020005C patent/LTPA2020005I1/lt unknown
- 2020-11-18 NO NO2020038C patent/NO2020038I1/no unknown
- 2020-11-19 FR FR20C1060C patent/FR20C1060I1/fr active Active
- 2020-11-19 HU HUS2000046C patent/HUS2000046I1/hu unknown
- 2020-11-19 CY CY2020036C patent/CY2020036I2/el unknown
- 2020-11-23 IL IL278914A patent/IL278914A/en unknown
-
2021
- 2021-09-20 US US17/479,649 patent/US20220142949A1/en active Pending
-
2022
- 2022-04-21 JP JP2022070231A patent/JP2022103194A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013001558A1 (es) | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. | |
EA201100969A1 (ru) | Солевые формы органического соединения | |
ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
AR060880A1 (es) | Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual | |
CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
UY32296A (es) | Nuevos compuestos | |
UY33353A (es) | Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion | |
CU20100159A7 (es) | Compuestos | |
EA201491607A1 (ru) | Модуляторы толлподобных рецепторов | |
UY33317A (es) | Nuevos derivados de pirazol | |
ECSP11011151A (es) | Compuestos purina | |
HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
CL2012000033A1 (es) | Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer. | |
CL2012001961A1 (es) | Método para tratar una enfermedad o trastorno en que aumentan los niveles de hormonas de estrés y/o disminuyen los niveles de hormonas de andrógenos, en que se administra un compuesto pirrolo-[1,2-c]-imidazol-bencil sustituido; su uso en insuficiencia cardíaca, entre otros; y compuestos pirrolo-[1,2-c]-imidazol-bencil sustituidos. | |
CL2007003440A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida | |
UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
NI200900183A (es) | Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer. | |
ECSP11011294A (es) | Compuestos de anillo fusionados y su uso | |
ECSP088700A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
AR079945A1 (es) | Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3) | |
NI201000173A (es) | Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre. | |
CL2007002637A1 (es) | Compuestos derivados de acido 2-fenoxinicotinico; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de dislipidemias, arteriosclerosis e insuficiencia cardiaca. | |
CL2012002823A1 (es) | Composición farmacéutica para el tratamiento de la diabetes y los trastornos relacionados, que comprende un sensibilizador de insulina seleccionado entre pioglitazona y rosiglitazona, glimepirida y metmorfina; formulación farmacéutica oral que la comprende; kit para tratar diabetes tipo ii; y uso de dicha formulación para tratar diabetes. | |
AR093327A1 (es) | Analogos quimericos de somatostatina-dopamina |